| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0000165 | Mapk cascade | Increases phenotype | PMID:15582350; PMID:17439724 |
| GO:0001890 | Placenta development | Decreases phenotype | PMID:24352370; PMID:26672737 |
| GO:0002053 | Positive regulation of mesenchymal cell proliferation | Decreases phenotype | PMID:26382659; PMID:26519041; PMID:27522124; PMID:27651373 |
| GO:0003031 | Detection of carbon dioxide | Increases phenotype | PMID:34502408 |
| GO:0003032 | Detection of oxygen | Increases phenotype | PMID:34502408 |
| GO:0006915 | Apoptotic process | Increases phenotype | PMID:15582350; PMID:17439724; PMID:17993583; PMID:20549697; PMID:22015466; PMID:23114405 |
| GO:0006979 | Response to oxidative stress | Increases phenotype | PMID:15582350 |
| GO:0007049 | Cell cycle | Decreases phenotype | PMID:17439724 |
| GO:0008283 | Cell population proliferation | Affects phenotype | PMID:17439724; PMID:20549697; PMID:23050982; PMID:25487476; PMID:29196881 |
| GO:0030324 | Lung development | Decreases phenotype | PMID:23354098; PMID:30995255 |
| GO:0033864 | Positive regulation of nad(p)h oxidase activity | Increases phenotype | PMID:26534761 |
| GO:0034633 | Retinol transport | Decreases phenotype | PMID:26672737 |
| GO:0042572 | Retinol metabolic process | Increases phenotype | PMID:24972641; PMID:26672737 |
| GO:0043065 | Positive regulation of apoptotic process | Increases phenotype | PMID:26649853 |
| GO:0045851 | Ph reduction | Increases phenotype | PMID:34502408 |
| GO:0048286 | Lung alveolus development | Decreases phenotype | PMID:34502408 |
| GO:0051451 | Myoblast migration | Decreases phenotype | PMID:27480986 |
| GO:0051881 | Regulation of mitochondrial membrane potential | Decreases phenotype | PMID:17439724 |
| GO:0060437 | Lung growth | Decreases phenotype | PMID:24352370; PMID:30106123 |
| GO:0060502 | Epithelial cell proliferation involved in lung morphogenesis | Decreases phenotype | PMID:31843527 |
| GO:0060539 | Diaphragm development | Decreases phenotype | PMID:26519041 |
| GO:0061046 | Regulation of branching involved in lung morphogenesis | Affects phenotype | PMID:31843527 |
| GO:0061112 | Negative regulation of bud outgrowth involved in lung branching | Increases phenotype | PMID:30106123 |
| GO:0061448 | Connective tissue development | Decreases phenotype | PMID:27480986 |
| GO:0070994 | Detection of oxidative stress | Increases phenotype | PMID:34502408 |
| GO:1904655 | Positive regulation of lung alveolus development | Decreases phenotype | PMID:26672737 |
| GO:1905111 | Positive regulation of pulmonary blood vessel remodeling | Increases phenotype | PMID:30418988 |
| GO:2000439 | Positive regulation of monocyte extravasation | Increases phenotype | PMID:30418988 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.